Cancer Biomarkers: The Promises and Challenges of Improving Detection and Treatment

cancer biomarkers the promises and challenges of improving implementing a national cancer clinical trials system cancer biomarkers the promises and challenges of improving cancer biomarkers the promises and challenges of improving a policy primer on diagnostics advamed institute of health and medicine division standards in molecular diagnostics for the discovery and the role of the lymphovascular system in cancer metastasis developing a framework for biomarker qualification for molecular characterization of circulating tumor cells in visit oncologyoptions options oncology practice the historical jesus and mythical christ ebook intervention treatment and recoverya practical guide to laboratory manual for comparative veterinary anatomy and envision math virginia teachers edition grade 3 topic 14 therapeutic uses of storytelling an interdisciplinary chapter 4 section 1 federalism the division of powers quiz student exploration energy conversions answer sheet tensor s4 s7 manual ecrops talent management solutions korn ferry executive english golden guide cbse class xii jupw guinness world records 2010 compax modern earth science answers angfit north west university undergraduate prospectus for 2016 pdf a shade of vampire 8 a shade of novak volume 8 ebook | imadev systems cost engineeringprogram affordability management study guide mountain building answers earth science

[1]  J. Ross.  Improving the accuracy of hormone receptor assays in breast cancer: an unmet medical need. , 2005, Future oncology.

[2]  Greg Yothers,et al.  Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience. , 2002, Journal of the National Cancer Institute.

[3]  E. Perez,et al.  HER2 testing by local, central, and reference laboratories in the NCCTG N9831 Intergroup Adjuvant Trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  L M Hinman,et al.  The drug diagnostic co-development concept paper Commentary from the 3rd FDA-DIA-PWG-PhRMA-BIO Pharmacogenomics Workshop , 2006, The Pharmacogenomics Journal.

[5]  T. Shibata,et al.  Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Peter J Neumann,et al.  Evidence-based and value-based formulary guidelines. , 2004, Health affairs.

[7]  Jason E. Stewart,et al.  Minimum information about a microarray experiment (MIAME)—toward standards for microarray data , 2001, Nature Genetics.

[8]  D. Rennie,et al.  Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative , 2003, BMJ : British Medical Journal.

[9]  H. Echizen,et al.  Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin , 2003, The Pharmacogenomics Journal.

[10]  V. Rich.  Personal communication , 1989, Nature.

[11]  A R Feinstein,et al.  Use of methodological standards in diagnostic test research. Getting better but still not good. , 1995, JAMA.

[12]  Nancy Breen,et al.  Progress in cancer screening practices in the United States , 2003, Cancer.

[13]  R. Lempicki,et al.  Evaluation of gene expression measurements from commercial microarray platforms. , 2003, Nucleic acids research.

[14]  G. Omenn,et al.  Standards for plasma and serum proteomics in early cancer detection: a needs assessment report from the national institute of standards and technology--National Cancer Institute Standards, Methods, Assays, Reagents and Technologies Workshop, August 18-19, 2005. , 2006, Clinical chemistry.

[15]  U. Reinhardt.  An information infrastructure for the pharmaceutical market. , 2004, Health affairs.

[16]  F. Hirsch,et al.  Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer , 2005, Current opinion in oncology.

[17]  Michael R. Green,et al.  Gene Expression , 1993, Progress in Gene Expression.

[18]  W. McGuire,et al.  Current status of estrogen receptors in human breast cancer , 1975, Cancer.

[19]  Peter A Kaufman,et al.  HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Daniel F. Hayes,et al.  Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful? , 2004, Breast Cancer Research and Treatment.

[21]  P. Klein,et al.  Concordance between central and local laboratory HER2 testing from a community-based clinical study. , 2006, Clinical breast cancer.

[22]  J. Foekens,et al.  Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: tasks of the Receptor and Biomarker Group of the European Organization for Research and Treatment of Cancer. , 2004, International journal of oncology.

[23]  K. Hudson.  Genetic Testing Oversight , 2006, Science.

[24]  B. Swanson.  Delivery of High-Quality Biomarker Assays , 2002, Disease markers.

[25]  A. Paradiso,et al.  The use of cell line standards to reduce HER-2/neu assay variation in multiple European cancer centers and the potential of automated image analysis to provide for more accurate cut points for predicting clinical response to trastuzumab. , 2004, American journal of clinical pathology.

[26]  Nancy A Obuchowski,et al.  Clinical evaluation of diagnostic tests. , 2005, AJR. American journal of roentgenology.

[27]  D. Slamon,et al.  Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[29]  R. Bast,et al.  2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  B. Ljung,et al.  HER2 testing in breast cancer: NCCN Task Force report and recommendations. , 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

[31]  Peter E Barker,et al.  Cancer biomarker validation: standards and process: roles for the National Institute of Standards and Technology (NIST). , 2003, Annals of the New York Academy of Sciences.